Mesoblast Limited

(NASDAQ:MESO)

Latest On Mesoblast Limited (MESO):

Date/Time Type Description Signal Details
2023-05-26 06:19 ESTNewsMesoblast Limited (MESO) Q3 2023 Earnings Call TranscriptN/A
2023-05-26 06:19 ESTNewsMesoblast GAAP EPS of -$0.025 beats by $0.13, revenue of $1.94M misses by $0.18MN/A
2023-05-04 20:51 ESTNewsMesoblast Has A Strong Upside PotentialN/A
2023-03-08 20:50 ESTNewsMesoblast stock surges ~10% on getting FDA review of graft versus host disease therapyN/A
2023-03-02 11:37 ESTNewsMesoblast Limited. (MESO) Q2 2023 Earnings Call TranscriptN/A
2023-02-28 14:47 ESTNewsMesoblast Limited 2023 Q2 - Results - Earnings Call PresentationN/A
2022-12-23 19:10 ESTNewsMesoblast and Oaktree extend availability of undrawn facilityN/A
2022-12-06 13:18 ESTNewsMesoblast stock falls 10% as Jefferies cuts rating to HoldN/A
2022-11-24 00:38 ESTNewsMesoblast Limited (MESO) Q1 2023 Earnings Call TranscriptN/A
2022-11-23 07:29 ESTNewsMesoblast GAAP EPS of -$0.0243 beats by $0.14, revenue of $1.5M misses by $1.82MN/A
2022-10-31 12:34 ESTNewsMesoblast reports operational and financial highlights for Q3N/A
2022-08-31 07:31 ESTNewsMesoblast Limited 2022 Q4 - Results - Earnings Call PresentationN/A
2022-08-31 07:31 ESTNewsMesoblast Limited (MESO) Q4 2022 Earnings Call TranscriptN/A
2022-08-31 07:31 ESTNewsMesoblast GAAP EPS of -$0.14, revenue of $10.21MN/A
2022-06-01 09:26 ESTNewsMesoblast GAAP EPS of -$0.03, revenue of $2MN/A
2022-02-02 13:18 ESTNewsNew medical chief at MesoblastN/A
2022-01-12 16:28 ESTNewsMesoblast’s rexlemestrocel-L results in durable pain reduction in degenerative disc diseaseN/A
2021-12-31 16:22 ESTNewsMesoblast to provide new data to FDA to support remestemcel-L BLA resubmissionN/A
2021-12-16 20:12 ESTNewsFDA’s OTAT in agreement pain reduction as primary endpoint in Mesoblast's Phase 3 programN/A
2021-12-14 07:58 ESTNewsMesoblast falls 8% after Novartis terminates deal prior to closingN/A
2021-12-06 08:59 ESTNewsMesoblast's rexlemestrocel-L shows treatment benefit in cardiovascular events in heart patientsN/A
2021-11-24 11:49 ESTNewsMesoblast EPS beats by $0.10, beats on revenueN/A
2021-11-22 16:32 ESTNewsMesoblast and Oaktree Capital refinance senior debt facilityN/A
2021-11-15 18:27 ESTNewsMesoblast's rexlemestrocel-l shows reduction in cardiovascular mortality, heart attacks and strokesN/A
2021-08-31 00:59 ESTNewsMesoblast EPS beats by $0.38N/A
2021-07-22 15:51 ESTNewsMesoblast reports FQ3 resultsN/A
2021-07-22 15:48 ESTNewsMesoblast provides update on rexlemestrocel-L in development for low back painN/A
2021-07-22 15:47 ESTNewsMesoblast reports respiratory function results of COVID-19 ARDS trialN/A
2021-07-22 15:47 ESTNewsMesoblast presents data showing mortality reduction of COVID-19 therapyN/A
2021-05-01 01:30 ESTNewsMESO, MOTS and SALM among premarket gainersN/A
2021-04-30 03:28 ESTNewsMesoblast's remestemcel-L reduces mortality by 46% in patients under age 65 with COVID-19 ARDSN/A
2021-04-08 03:05 ESTNewsMaxim upgrades Mesoblast to buy, sets $18 price targetN/A
2021-03-17 15:22 ESTAnalyst RatingThe Analyst Target Price has decreased from $14.5 to $13.7.Neutral
2021-03-16 23:50 ESTAnalyst RatingThe Analyst Target Price has decreased from $14.96 to $14.5.Neutral
2021-03-03 00:44 ESTNewsMesoblast announces a private placement of $110 millionN/A
2021-03-01 01:44 ESTEarnings EstimateAn EPS average of $0.03 is estimated for the quarter ending on March 31, 2021.Buy
2021-02-28 05:42 ESTFinancialsCompany financials have been released.Neutral
2021-02-17 14:54 ESTNewsMesoblast gains as remestemcel-l shows positive action in MIS-C post COVID-19N/A
2021-02-15 13:38 ESTAnalyst RatingThe Analyst Target Price has increased from $14.29 to $14.96.Buy
2021-02-12 12:18 ESTNewsMesoblast announces data from Phase 3 study in chronic back painN/A
2021-01-29 11:38 ESTNewsMesoblast issues FQ2 operational and financial updateN/A
2021-01-27 14:09 ESTAnalyst RatingThe Analyst Target Price has decreased from $14.96 to $14.29.Neutral
2021-01-19 22:20 ESTNewsMesoblast's Time May Be UpN/A
2021-01-11 12:34 ESTNewsMesoblast's rexlemestrocel-l reduces heart attacks, strokesN/A
2020-12-25 10:33 ESTAnalyst RatingThe Analyst Target Price has decreased from $16.45 to $14.96.Neutral
2020-12-24 16:56 ESTNewsMesoblast: The Future Looks BleakN/A
2020-12-24 02:40 ESTAnalyst RatingThe Analyst Target Price has increased from $14.96 to $16.45.Buy
2020-12-23 18:45 ESTAnalyst RatingThe Analyst Target Price has decreased from $15.39 to $14.96.Neutral
2020-12-20 22:34 ESTAnalyst RatingThe Analyst Target Price has decreased from $16.82 to $15.39.Neutral
2020-12-18 05:21 ESTNewsMesoblast shares plunge 32% after stem-cell therapy not likely to meet target for reducing mortality due to COVID-19N/A

About Mesoblast Limited (MESO):

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develop and commercialize cell therapy for the treatment of chronic low back pain. The company was founded in 2004 and is headquartered in Melbourne, Australia.

MESO Quotes by TradingView

See Advanced Chart

General

  • Name Mesoblast Limited
  • Symbol MESO
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 102
  • Fiscal Year EndJune
  • IPO Date2015-11-13
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.mesoblast.com
View More

Valuation

  • Forward PE 454.55
  • Price/Sales (Trailing 12 Mt.) 62.46
  • Price/Book (Most Recent Quarter) 2.28
  • Enterprise Value Revenue 70.47
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$0.29
  • Next Year EPS Estimate $0.17
  • Operating Margin -682%
  • Return on Assets -10%
  • Return on Equity -19%
  • Revenue 16.45 million
  • Earnings Per Share -$0.91
  • Revenue Per Share $0.15
  • Gross Profit 6.85 million
  • Quarterly Earnings Growth 1.6%
View More

Highlights

  • Market Capitalization 1.26 billion
  • EBITDA -78815000
  • Analyst Target Price $13.7
  • Book Value Per Share $4.42
View More

Share Statistics

  • Shares Outstanding 129.62 million
  • Shares Float 101.69 million
  • % Held by Insiders <1%
  • % Held by Institutions 2.87%
  • Shares Short 1.88 million
  • Shares Short Prior Month 2.82 million
  • Short Ratio 4.29
  • Short % of Shares Outstanding 2%
View More

Technicals

  • Beta 2.71
  • 52 Week High $21.28
  • 52 Week Low $3.12
  • 50 Day Moving Average 9.64
  • 200 Day Moving Average 12.23
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Mesoblast Limited (MESO) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Mesoblast Limited (MESO) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-02-26$N/A-$0.22-$0.15-43.61%
2020-09-302020-11-19$N/A-$0.21-$0.2619.04%
2020-06-302020-08-26$N/A-$0.30-$0.21-42.52%
2020-03-312020-05-27$12.08 million-$0.14-$0.1612.62%
2019-12-312020-02-26$2.21 million-$0.23-$0.13-71.64%
2019-09-302019-11-25$16.87 million-$0.06-$0.1970.27%
2019-06-302019-08-29$1.25 million-$0.21-$0.2724.04%
2019-03-312019-05-30$1.25 million-$0.25-$0.263.85%
2018-12-312019-02-20$1.87 million-$0.25-$0.23-8.7%
2018-09-302018-11-15$11.64 million-$0.20-$0.2311.52%
2018-06-302018-08-29$1.7 million-$0.22-$0.232.19%
2018-03-312018-05-30$1.07 million-$0.22-$0.22-1.59%
2017-12-312018-02-27$13.28 million$0.15-$0.20172.03%
2017-09-302017-11-14$1.11 million-$0.08-$0.2467.21%
2017-06-302017-08-29$473000-$0.32-$0.21-50.59%
2017-03-312017-05-24$820000-$0.12-$0.1935.26%
2016-12-312017-02-26$433000-$0.26-$0.20-34.92%
2016-09-302016-11-14$218000-$0.05-$0.2175.05%
2016-06-302016-08-24$26.62 million$0.64-$0.20423.54%
2016-03-312016-05-09$3.85 million-$0.04-$0.1263.7%
2015-12-312016-02-16$3.75 million-$0.31-$0.17-80.75%
2015-09-302015-12-16$7.25 million-$0.19

Mesoblast Limited (MESO) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Apr 30 2020 Mar 31 2020
Research Development N/A N/A N/A N/A 14.38 million
Income Before Tax N/A N/A N/A N/A -17.22 million
Selling General Administrative N/A N/A N/A N/A 5.73 million
Gross Profit N/A N/A N/A N/A N/A
Ebit N/A N/A N/A N/A -12.54 million
Operating Income N/A N/A N/A N/A -15.64 million
Income Tax Expense 74000 -730000 -3.26 million -3.26 million -1.96 million
Total Revenue N/A N/A N/A N/A 12.08 million
Cost of Revenue N/A N/A N/A N/A N/A
Total Other Income Expense Net N/A N/A N/A N/A 2.04 million
Net Income From Continuing Operations N/A N/A N/A N/A -15.26 million
Net Income Applicable to Common Shares -25.69 million -24.54 million -32.61 million -32.61 million -15.26 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Apr 30 2020 Mar 31 2020 Jan 31 2020
Investments -81000 -1.87 million -1.87 million -693000 -693000
Change to Liabilities N/A N/A 6.2 million 403000 403000
Total Cash Flow from Investing Activities N/A N/A -1.87 million -693000 -693000
Net Borrowings N/A N/A -406000 -524000 -524000
Total Cash Flow from Financial Activities 6.54 million 88.92 million 88.92 million -65000 -65000
Change to Operating Activities N/A N/A 2.54 million -6.51 million -6.51 million
Change in Cash N/A 67.47 million 67.47 million -20.65 million -20.65 million
Total Cash from Operating Activities N/A N/A -19.58 million -19.9 million -19.9 million
Depreciation N/A N/A N/A 946000 946000
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A 64000 64000
Other Cash Flow from Financing Activities N/A N/A -4.07 million -47000 -47000
Change to Net Income N/A N/A 1.84 million 463000 463000
Capital Expenditures 81000 841000 841000 693000 693000
Balance Sheet:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Apr 30 2020 Mar 31 2020
Total Liabailities N/A N/A N/A N/A 177.98 million
Total Stockholder Equity N/A N/A N/A N/A 487.81 million
Other Current Liabilities 18.31 million 22.22 million N/A N/A N/A
Total Assets N/A N/A N/A N/A 665.79 million
Common Stock 1.07 billion 1.06 billion 1.05 billion N/A 960.45 million
Other Current Assets N/A N/A N/A 1.05 billion N/A
Retained Earnings -598.99 million -573.3 million -548.76 million -548.76 million -516.15 million
Other Liabilities 21.94 million 23.22 million 30.79 million 30.79 million 35.58 million
Other Assets 3.21 million 3.33 million 3.31 million 3.31 million 3.24 million
Cash N/A N/A N/A N/A 60.08 million
Total Current Liabilities 91.04 million 87.7 million N/A N/A 76.69 million
Other Stockholder Equity 52.19 million 48.8 million 46.63 million 46.63 million 43.51 million
Property, Plant & Equipment 10.41 million 10.33 million 10.27 million 10.27 million 9.44 million
Total Current Assets 90.46 million 115.74 million N/A N/A 69.39 million
Long Term Investments N/A N/A N/A N/A 1.77 million
Net Tangible Assets -62.6 million -42.71 million -32.28 million -32.28 million -94.13 million
Short Term Investments N/A N/A N/A N/A N/A
Long Term Debt N/A N/A N/A N/A 59.95 million
Inventory N/A N/A N/A N/A N/A
Accounts Payable 28.61 million 27.6 million N/A N/A 19.48 million

Mesoblast Limited (MESO) Chart:

Mesoblast Limited (MESO) News:

Below you will find a list of latest news for Mesoblast Limited (MESO) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Mesoblast Limited (MESO) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-10-1730CALL0 0808.95TRUE00
2025-10-1756.8CALL0 0543.02TRUE00
2025-10-1764.8CALL0 4515.25TRUE00
2025-10-1770CALL0 0438.79TRUE00
2025-10-1783.4CALL0 4407.68TRUE00
2025-10-1792.65CALL0 3368.76TRUE00
2025-10-17106.5CALL0 369269.3TRUE00
2025-10-17114.5CALL0 10292.94TRUE00
2025-10-17126.75CALL30 10790TRUE6.750
2025-10-17133.5CALL0 182202.44TRUE00
2025-10-17145CALL9 396171.94TRUE1.940.63
2025-10-17153.6CALL3 136792.46TRUE1.350.6
2025-10-17161.5CALL0 49540.68TRUE00
2025-10-17172.05CALL4 44090.13TRUE0.970.9
2025-10-17180.45CALL0 731100.25TRUE00
2025-10-17191CALL1 15189.74FALSE10
2025-10-17200.5CALL59 305876.96FALSE0.50
2025-10-17211CALL0 98152.67FALSE00
2025-10-17220.1CALL0 7179.25FALSE00
2025-10-17230.1CALL2 18280.3FALSE0.10
2025-10-17240.15CALL0 8237.76FALSE00
2025-10-17250.1CALL0 11272.48FALSE00
2025-10-17300.2CALL0 6569.42FALSE00
2025-10-1730PUT0 00FALSE00
2025-10-1750PUT0 00FALSE00
2025-10-1760.35PUT0 2750FALSE00
2025-10-1770PUT0 01411.63FALSE00
2025-10-1780.1PUT0 211203.45FALSE00
2025-10-1790.1PUT0 21052.2FALSE00
2025-10-17100.4PUT0 218932.98FALSE00
2025-10-17110.35PUT0 25834.27FALSE00
2025-10-17120.05PUT2 1630126.23FALSE0.050
2025-10-17130.4PUT0 38675.46FALSE00
2025-10-17140.15PUT12 21111.37FALSE0.150
2025-10-17150.1PUT220 100780.22FALSE0.10
2025-10-17160.33PUT10 3590.11FALSE-0.22-0.4
2025-10-17174.5PUT0 10161.37FALSE00
2025-10-17181PUT1 188.02FALSE10
2025-10-17190PUT0 0222.55TRUE00
2025-10-17205.3PUT0 1000147.72TRUE00
2025-10-17210PUT0 068.55TRUE00
2025-10-17220PUT0 086.75TRUE00
2025-10-17230PUT0 0100.7TRUE00
2025-10-17240PUT0 0147.85TRUE00
2025-10-17250PUT0 0161.27TRUE00
2025-10-17300PUT0 0210.84TRUE00
2025-11-21100CALL0 084.99TRUE00
2025-11-21110CALL0 00TRUE00
2025-11-21120CALL0 071.41TRUE00
2025-11-21130CALL0 087.05TRUE00
2025-11-21140CALL0 076.53TRUE00
2025-11-21150CALL0 0115.74TRUE00
2025-11-21160CALL0 0102.79TRUE00
2025-11-21173.4CALL2 20101.59TRUE1.20.55
2025-11-21180CALL0 0128.31TRUE00
2025-11-21191.8CALL12 075.61FALSE1.80
2025-11-21201.8CALL1 089.6FALSE1.80
2025-11-21210CALL0 079.51FALSE00
2025-11-21220CALL0 0172.79FALSE00
2025-11-21250CALL0 0222.89FALSE00
2025-11-21300CALL0 0192.85FALSE00
2025-11-21100PUT0 0487.46FALSE00
2025-11-21110PUT0 0240.67FALSE00
2025-11-21120PUT0 0272.24FALSE00
2025-11-21130PUT0 0297.42FALSE00
2025-11-21140PUT0 0292.53FALSE00
2025-11-21151.5PUT0 125138.95FALSE00
2025-11-21162PUT0 131123.36FALSE00
2025-11-21170PUT0 0130.1FALSE00
2025-11-21180PUT0 0128.34FALSE00
2025-11-21190PUT0 088.96TRUE00
2025-11-21200PUT0 085.17TRUE00
2025-11-21210PUT0 084.77TRUE00
2025-11-21220PUT0 090.32TRUE00
2025-11-21250PUT0 0121.61TRUE00
2025-11-21300PUT0 0100.66TRUE00
2026-01-160.50CALL0 200TRUE00
2026-01-1610CALL0 100TRUE00
2026-01-161.50CALL0 00TRUE00
2026-01-1620CALL0 1000TRUE00
2026-01-162.50CALL0 12610TRUE00
2026-01-1630CALL0 0193.16TRUE00
2026-01-1640CALL0 100TRUE00
2026-01-1658CALL0 15133.7TRUE00
2026-01-16610.4CALL0 2594.35TRUE00
2026-01-1678.8CALL0 407167.85TRUE00
2026-01-1687.84CALL0 0135.4TRUE00
2026-01-1690CALL0 0129.21TRUE00
2026-01-16105.8CALL0 211103.64TRUE00
2026-01-16115.95CALL0 1899.07TRUE00
2026-01-16125.4CALL0 5730TRUE00
2026-01-16133.4CALL0 14076.33TRUE00
2026-01-16145.22CALL5 16865.69TRUE5.220
2026-01-16155CALL2 61581.78TRUE50
2026-01-16163.1CALL0 60562.78TRUE00
2026-01-16173.8CALL10 29778.74TRUE3.80
2026-01-16183.2CALL1 27375.28TRUE0.760.31
2026-01-16192.75CALL486 119574.56FALSE0.750.38
2026-01-16202.35CALL56 218573.86FALSE0.580.33
2026-01-16212.05CALL306 88974.53FALSE0.60.41
2026-01-16221.8CALL202 67975.43FALSE0.40.29
2026-01-16231.5CALL222 97474.04FALSE1.50
2026-01-16241.3CALL305 36274.42FALSE0.30.3
2026-01-16251.25CALL244 39178.36FALSE1.250
2026-01-16300.2CALL0 238109.31FALSE00
2026-01-160.50PUT0 0343.62FALSE00
2026-01-1610PUT0 0236.05FALSE00
2026-01-161.50PUT0 0189.92FALSE00
2026-01-1620PUT0 20161.02FALSE00
2026-01-162.50PUT0 0158.33FALSE00
2026-01-1630PUT0 00FALSE00
2026-01-1640PUT0 0153.53FALSE00
2026-01-1650PUT0 00FALSE00
2026-01-1660PUT0 0627.07FALSE00
2026-01-1670.8PUT0 3504.15FALSE00
2026-01-1681.2PUT0 7429.55FALSE00
2026-01-1690.93PUT0 22375.55FALSE00
2026-01-16101.22PUT0 63201.21FALSE00
2026-01-16112.85PUT0 3137.88FALSE00
2026-01-16121.5PUT0 30140.56FALSE00
2026-01-16132.6PUT0 11144.78FALSE00
2026-01-16145.6PUT0 5100.9FALSE00
2026-01-16152.75PUT0 5897.08FALSE00
2026-01-16162.85PUT0 21105.69FALSE00
2026-01-16172.95PUT0 13100.83FALSE00
2026-01-16184.4PUT0 1090.56FALSE00
2026-01-16196.77PUT0 3383.75TRUE00
2026-01-16207.19PUT0 185.66TRUE00
2026-01-16210PUT0 084.6TRUE00
2026-01-16220PUT0 077.33TRUE00
2026-01-16230PUT0 090.7TRUE00
2026-01-16240PUT0 093.03TRUE00
2026-01-162510.8PUT0 597.48TRUE00
2026-01-16300PUT0 087.12TRUE00
2026-04-1750CALL0 099.57TRUE00
2026-04-1788.01CALL0 2101.57TRUE00
2026-04-1790CALL0 069.57TRUE00
2026-04-17107CALL0 688.69TRUE00
2026-04-17110CALL0 092.34TRUE00
2026-04-17120CALL0 079.33TRUE00
2026-04-17135.1CALL0 1973.45TRUE00
2026-04-17146CALL1 9067.49TRUE60
2026-04-17154.1CALL0 5773.36TRUE00
2026-04-17164.1CALL0 50467.34TRUE00
2026-04-17173.1CALL0 19767.28TRUE00
2026-04-17184.03CALL5 23769.85TRUE4.030
2026-04-17193.8CALL110 10273.17FALSE3.80
2026-04-17203.35CALL310 134071.49FALSE0.650.24
2026-04-17212.49CALL0 238176.2FALSE00
2026-04-17252.2CALL560 14775.29FALSE0.550.33
2026-04-17301.45CALL308 43376.92FALSE0.50.53
2026-04-1750PUT0 00FALSE00
2026-04-1780PUT0 0153.86FALSE00
2026-04-1790PUT0 0158.27FALSE00
2026-04-17101.4PUT0 3162.18FALSE00
2026-04-17111.4PUT0 15100.05FALSE00
2026-04-17121.2PUT1 1783.94FALSE1.20
2026-04-17131.46PUT15 1881.24FALSE-0.24-0.14
2026-04-17140PUT0 0114.93FALSE00
2026-04-17150PUT0 086.66FALSE00
2026-04-17160PUT0 079.04FALSE00
2026-04-17170PUT0 086.91FALSE00
2026-04-17186PUT0 4088.91FALSE00
2026-04-17190PUT0 086.73TRUE00
2026-04-17200PUT0 085.96TRUE00
2026-04-17210PUT0 082.79TRUE00
2026-04-17250PUT0 094.6TRUE00
2026-04-17300PUT0 072.04TRUE00
2027-01-1530CALL0 00TRUE00
2027-01-1550CALL0 00TRUE00
2027-01-1580CALL0 050.54TRUE00
2027-01-15100CALL0 056.09TRUE00
2027-01-15120CALL0 063.61TRUE00
2027-01-15130CALL0 00TRUE00
2027-01-15150CALL0 064.98TRUE00
2027-01-15175CALL0 5070.13TRUE00
2027-01-15203.57CALL0 870.74FALSE00
2027-01-15223.63CALL0 171.79FALSE00
2027-01-15253.3CALL0 174.7FALSE00
2027-01-15272.75CALL0 6373.71FALSE00
2027-01-15300CALL0 074.19FALSE00
2027-01-1530PUT0 00FALSE00
2027-01-1550PUT0 00FALSE00
2027-01-1580PUT0 0209.05FALSE00
2027-01-15100PUT0 0162.18FALSE00
2027-01-15120PUT0 0130.87FALSE00
2027-01-15130PUT0 00FALSE00
2027-01-15150PUT0 088.81FALSE00
2027-01-15170PUT0 085.7FALSE00
2027-01-15200PUT0 086.21TRUE00
2027-01-15220PUT0 087.47TRUE00
2027-01-15250PUT0 084.75TRUE00
2027-01-15270PUT0 084.24TRUE00
2027-01-15300PUT0 085.49TRUE00
2028-01-2130CALL0 00TRUE00
2028-01-2150CALL0 00TRUE00
2028-01-2180CALL0 049.93TRUE00
2028-01-21109CALL0 557.52TRUE00
2028-01-21120CALL0 059.07TRUE00
2028-01-21150CALL0 063.6TRUE00
2028-01-21176.39CALL0 166.26TRUE00
2028-01-21200CALL0 068.08FALSE00
2028-01-21220CALL0 065.91FALSE00
2028-01-21250CALL0 067.81FALSE00
2028-01-21270CALL0 066.95FALSE00
2028-01-21300CALL0 067.32FALSE00
2028-01-2130PUT0 00FALSE00
2028-01-2150PUT0 00FALSE00
2028-01-2180PUT0 0160.97FALSE00
2028-01-21100PUT0 087.08FALSE00
2028-01-21120PUT0 085.5FALSE00
2028-01-21156PUT0 1087.93FALSE00
2028-01-21170PUT0 084.13FALSE00
2028-01-21200PUT0 086.72TRUE00
2028-01-21220PUT0 084.1TRUE00
2028-01-21250PUT0 086.62TRUE00
2028-01-21270PUT0 086.11TRUE00
2028-01-21300PUT0 087.23TRUE00
2030-12-18100.2CALL456 3400TRUE-3.3-0.94
2030-12-18250PUT 0TRUE00

Latest MESO Trades:

Date Shares Price
Jun 13, 2022 7:54 PM EST100$2.645
Jun 13, 2022 7:54 PM EST100$2.645
Jun 13, 2022 7:55 PM EST100$2.64
Jun 13, 2022 7:57 PM EST186$2.66
Jun 13, 2022 7:57 PM EST14$2.66

Mesoblast Limited (MESO) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020031530/0001564590-20-031530-index.htm
2020-01-30SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1345099/000119312520019148/0001193125-20-019148-index.htm
2020-07-27S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1345099/000121390020018628/0001213900-20-018628-index.htm
2020-05-26DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1345099/000134509920000001/0001345099-20-000001-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1345099/000142284920000077/0001422849-20-000077-index.htm
2019-09-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019034209/0001564590-19-034209-index.htm
2019-09-0920-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1345099/000156459019034304/0001564590-19-034304-index.htm
2019-09-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019034483/0001564590-19-034483-index.htm
2019-10-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019036315/0001564590-19-036315-index.htm
2019-10-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019036431/0001564590-19-036431-index.htm
2019-10-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019036737/0001564590-19-036737-index.htm
2019-10-226-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019037256/0001564590-19-037256-index.htm
2019-11-016-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019039260/0001564590-19-039260-index.htm
2019-11-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019041204/0001564590-19-041204-index.htm
2019-11-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019044600/0001564590-19-044600-index.htm
2019-11-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019044601/0001564590-19-044601-index.htm
2019-11-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019044825/0001564590-19-044825-index.htm
2019-12-126-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019045775/0001564590-19-045775-index.htm
2019-12-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019046754/0001564590-19-046754-index.htm
2020-01-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020000984/0001564590-20-000984-index.htm
2020-01-226-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020001658/0001564590-20-001658-index.htm
2020-02-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020003090/0001564590-20-003090-index.htm
2020-02-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020003512/0001564590-20-003512-index.htm
2020-02-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020004688/0001564590-20-004688-index.htm
2020-02-266-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020006501/0001564590-20-006501-index.htm
2020-02-286-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020007597/0001564590-20-007597-index.htm
2020-03-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020009861/0001564590-20-009861-index.htm
2020-03-206-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020011865/0001564590-20-011865-index.htm
2020-03-256-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020012613/0001564590-20-012613-index.htm
2020-04-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020014830/0001564590-20-014830-index.htm
2020-04-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020015584/0001564590-20-015584-index.htm
2020-04-096-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020016005/0001564590-20-016005-index.htm
2020-04-206-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020017344/0001564590-20-017344-index.htm
2020-04-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020018322/0001564590-20-018322-index.htm
2020-05-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020020611/0001564590-20-020611-index.htm
2020-05-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020022226/0001564590-20-022226-index.htm
2020-05-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020025586/0001564590-20-025586-index.htm
2020-05-196-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020026055/0001564590-20-026055-index.htm
2020-05-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020026914/0001564590-20-026914-index.htm
2020-05-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020027408/0001564590-20-027408-index.htm
2020-05-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020027410/0001564590-20-027410-index.htm
2020-06-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020028116/0001564590-20-028116-index.htm
2020-06-186-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020029698/0001564590-20-029698-index.htm
2020-06-266-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020030668/0001564590-20-030668-index.htm
2020-07-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020031530/0001564590-20-031530-index.htm
2020-07-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020031863/0001564590-20-031863-index.htm
2020-07-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020032147/0001564590-20-032147-index.htm
2020-07-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020033456/0001564590-20-033456-index.htm
2020-08-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020035263/0001564590-20-035263-index.htm
2020-08-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020038657/0001564590-20-038657-index.htm
2020-08-126-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020039445/0001564590-20-039445-index.htm
2020-08-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020040358/0001564590-20-040358-index.htm
2020-08-256-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020041082/0001564590-20-041082-index.htm
2020-08-316-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020041869/0001564590-20-041869-index.htm
2020-09-0320-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1345099/000156459020042401/0001564590-20-042401-index.htm
2020-09-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020042407/0001564590-20-042407-index.htm
2020-09-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020042713/0001564590-20-042713-index.htm
2020-09-166-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020043641/0001564590-20-043641-index.htm
2020-09-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020043751/0001564590-20-043751-index.htm
2020-10-056-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020045777/0001564590-20-045777-index.htm
2020-10-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020046432/0001564590-20-046432-index.htm
2020-10-236-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020047335/0001564590-20-047335-index.htm
2020-10-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020048488/0001564590-20-048488-index.htm
2020-11-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020049709/0001564590-20-049709-index.htm